Design Therapeutics

DSGN

ATLANTA, GA – – (ACCESSWIRE – December 29, 2022) – – Holzer & Holzer, LLC is investigating whether Design Therapeutics, Inc. (“Design Therapeutics” or the “Company”) (NASDAQ: DSGN) complied with federal securities laws.  On December 7, 2022, Design Therapeutics announced initial results from the Company’s Phase 1 clinical trial in patients with Friedreich ataxia. As part of the initial results, the Company disclosed that “16 (73%) patients on DT-216 and eight (73%) patients on placebo reported at least one treatment-emergent adverse event.” Following this disclosure, the Company’s stock price dropped.

If you purchased Design Therapeutics stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at  cholzer@holzerlaw.com  or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website https://holzerlaw.com/case/design-therapeutics/  to discuss your legal rights.

Registration Deadline

Lead Plaintiff Deadline Has Passed

Submit Your Information

Name(Required)
Address
MM slash DD slash YYYY
Shares Purchased(Required)
Number of Shares Acquired
Acquisition Price Per Share
 
MM slash DD slash YYYY
Shares Sold
Number of Shares Sold
Selling Price Per Share
 
By clicking on the button below, I am requesting Holzer & Holzer, LLC send me documents necessary to retain the firm.